Loading...
•
Jun 30, 2024
Amedisys Q2 2024 Earnings Report
Amedisys reported an increase in net service revenue and a return to profitability in Q2 2024, driven by growth in home health and hospice segments, despite incurring merger-related expenses.
Key Takeaways
Amedisys, Inc. reported its financial results for the three months ended June 30, 2024. Net service revenue increased to $591.2 million compared to $553.0 million in 2023. Net income attributable to Amedisys, Inc. was $32.3 million, compared to a net loss of $80.3 million in 2023. Adjusted net income per diluted share was $1.32, compared to $1.37 in 2023.
Net service revenue increased by $38.2 million to $591.2 million compared to Q2 2023.
Net income attributable to Amedisys, Inc. was $32.3 million, inclusive of $11.9 million in merger-related expenses.
Adjusted EBITDA was $73.2 million compared to $74.6 million in 2023.
Net income attributable to Amedisys, Inc. per diluted share of $0.98 compared to net loss attributable to Amedisys, Inc. per diluted share of $2.46 in 2023.
Amedisys
Amedisys
Forward Guidance
Amedisys will not conduct a quarterly earnings call due to the pending merger with UnitedHealth Group Incorporated.